drug · intermediate · complete
Luxturna (voretigene neparvovec)
A one-time subretinal AAV2 gene therapy that supplies RPE65 to the retina in inherited retinal dystrophy.
Also called: voretigene neparvovec, AAV2-hRPE65v2
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
What it is and what happened
Luxturna is an AAV2 gene therapy injected under the retina to give cells a working RPE65 gene. In its randomised phase 3 trial, 13 of 20 treated people passed the mobility test at the lowest light level against none of the controls, with no product-related serious adverse events. It is approved. 1
Reported, not yet replicated
The decisive trial more
The phase 3 trial enrolled 31 people at two US sites between November 2012 and November 2013, randomised 2:1; one person from each group withdrew, leaving 20 treated and 9 controls. Mean change at one year was 1.8 versus 0.2 light levels (difference 1.6, 95% CI 0.72 to 2.41, p=0.0013). No product-related serious adverse events or deleterious immune responses occurred. The trial was open-label; assessing graders were masked and the primary result rests on one functional test. 1
Reported, not yet replicated
Why it worked and what it costs more
Local delivery is the point. FDA reported no clinically significant cytotoxic T-cell response to AAV2 or RPE65 in 41 subjects, but notes that corticosteroids may have decreased the immune reaction. The label lists cataract in 20%, retinal tear in 10% and raised eye pressure in 15%, which come from the surgery and steroids as much as from the vector. 23
Reported, not yet replicated
Promoter and selectivity deep
The vector uses a strong, ubiquitous hybrid promoter, as Zolgensma does. Selectivity comes from the route (under the retina), not from the on-switch. 34
Reported, not yet replicated
Modality
Targets
Pathways
Indications
Identifiers
Nonproprietary name
voretigene neparvovec
Mechanism
An AAV2 vector carries human RPE65 under a cytomegalovirus enhancer and chicken beta-actin promoter. The visual-cycle enzyme is missing in these patients; the vector gives retinal cells a working copy. 3
Reported, not yet replicated
Delivery route
Must survive
It is injected under the retina, 1.5 x 10^11 vector genomes per eye in 0.3 mL, so the vector stays in a small closed space and meets a very small dose of the immune system; the label recommends oral corticosteroid cover around each injection. 2
Reported, not yet replicated
Side effects
Cataract
In 20% of subjects (label Table 1); these are surgery and steroid effects as much as vector effects. 2
Reported, not yet replicated
Verdict
Outcome
worked
Why
In the phase 3 trial (31 enrolled, open-label, 2:1 randomised, masked graders), the mean change on the mobility test was 1.8 versus 0.2 light levels (difference 1.6, 95% CI 0.72 to 2.41, p=0.0013) and 13 of 20 (65%) treated versus none of the controls passed at 1 lux. The FDA analysis (21 versus 10) found 11 of 21 (52%) versus 1 of 10 (10%) improved by 2 or more levels. The effect was maintained over 2 years of follow-up. It worked in a small closed compartment, with non-dividing target cells, a tiny dose and steroid cover; FDA noted corticosteroids may have decreased the immune reaction, so the clean immune result is partly steroid-dependent. 123
Reported, not yet replicated
Teach this
In one sentence
Luxturna succeeds by keeping a small dose of gene-carrying virus inside a closed compartment, the eye, where it meets few immune cells. 21
Reported, not yet replicated
The five-minute version
RPE65 is a visual-cycle enzyme that these patients lack. A one-time injection under the retina delivers the gene in an AAV2 shell. In a randomised open-label trial the treated group improved on a mobility test under dim light and the control group did not, with no product-related serious adverse events; the label still records cataract, retinal tears and raised eye pressure. 12
Reported, not yet replicated
What a listener will ask
Why a strong always-on promoter?
Delivery supplies the selectivity: the injection puts the vector where it is needed.
Would an intravenous route work the same way?
The Zolgensma case shows systemic dosing sends vector to the liver as well, with a boxed warning; this has not been tested for Luxturna in these sources.
The common wrong idea
The clean safety record shows AAV is harmless.
It shows a small dose in a closed space with steroid cover is well tolerated; the same vector idea given systemically at high dose has produced liver failure.
The one citation to hand over: 1
Still open here
- Durability past the 2-year statement in the regulatory review: no primary long-term paper was opened.
Not yet written: Assays used, Off targets.
Linked from
Sources
- Russell S, Bennett J, Wellman JA, et al.. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. The Lancet (2017). paper; opened 2026-11-17 all records citing this
- US Food and Drug Administration. LUXTURNA (voretigene neparvovec-rzyl) prescribing information. FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- US Food and Drug Administration. FDA Summary Basis for Regulatory Action: Luxturna, 18 December 2017. FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- US Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) prescribing information, revision 6/2026. FDA (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2017
- Regulatory status
- approved
- Status
- complete
- Last updated
- 2026-11-19
- Record
- content/drugs/luxturna.json